Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Budhawant C, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Poonawalla CS, Shaligram U, Kapse D, Gunale B. Kulkarni PS, et al. Among authors: bonhomme cj. Hum Vaccin Immunother. 2024 Dec 31;20(1):2304974. doi: 10.1080/21645515.2024.2304974. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38512394 Free PMC article. Clinical Trial.
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Vadakkedath R, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Shaligram U, Kapse D, Gunale B; COVISHIELD Study Group. Kulkarni PS, et al. Among authors: bonhomme cj. EClinicalMedicine. 2021 Dec;42:101218. doi: 10.1016/j.eclinm.2021.101218. Epub 2021 Nov 30. EClinicalMedicine. 2021. PMID: 34870133 Free PMC article.
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
Bonhomme ME, Bonhomme CJ, Strelow L, Chaudhari A, Howlett A, Breidenbach C, Hester J, Hammond C, Fuzy M, Harvey L, Swanner V, Ellis J, Greway RR, Pisciella VA, Green T, Kierstead L. Bonhomme ME, et al. Among authors: bonhomme cj. PLoS One. 2022 Feb 7;17(2):e0262922. doi: 10.1371/journal.pone.0262922. eCollection 2022. PLoS One. 2022. PMID: 35130298 Free PMC article.
LCMV glycosylation modulates viral fitness and cell tropism.
Bonhomme CJ, Knopp KA, Bederka LH, Angelini MM, Buchmeier MJ. Bonhomme CJ, et al. PLoS One. 2013;8(1):e53273. doi: 10.1371/journal.pone.0053273. Epub 2013 Jan 7. PLoS One. 2013. PMID: 23308183 Free PMC article.
11 results